99 related articles for article (PubMed ID: 20846263)
1. Epigenetic inactivation of HOXA5 and MSH2 gene in clear cell renal cell carcinoma.
Yoo KH; Park YK; Kim HS; Jung WW; Chang SG
Pathol Int; 2010 Oct; 60(10):661-6. PubMed ID: 20846263
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel epigenetic markers for clear cell renal cell carcinoma.
Dalgin GS; Drever M; Williams T; King T; DeLisi C; Liou LS
J Urol; 2008 Sep; 180(3):1126-30. PubMed ID: 18639284
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic inactivation of Homeobox A5 gene in nonsmall cell lung cancer and its relationship with clinicopathological features.
Kim DS; Kim MJ; Lee JY; Lee SM; Choi JY; Yoon GS; Na YK; Hong HS; Kim SG; Choi JE; Lee SY; Park JY
Mol Carcinog; 2009 Dec; 48(12):1109-15. PubMed ID: 19554572
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and diagnostic relevance of hypermethylated in cancer 1 (HIC1) CpG island methylation in renal cell carcinoma.
Eggers H; Steffens S; Grosshennig A; Becker JU; Hennenlotter J; Stenzl A; Merseburger AS; Kuczyk MA; Serth J
Int J Oncol; 2012 May; 40(5):1650-8. PubMed ID: 22327210
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation profile of kidney cancer.
Dulaimi E; Ibanez de Caceres I; Uzzo RG; Al-Saleem T; Greenberg RE; Polascik TJ; Babb JS; Grizzle WE; Cairns P
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3972-9. PubMed ID: 15217927
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma.
Okuda H; Toyota M; Ishida W; Furihata M; Tsuchiya M; Kamada M; Tokino T; Shuin T
Oncogene; 2006 Mar; 25(12):1733-42. PubMed ID: 16278676
[TBL] [Abstract][Full Text] [Related]
7. Methylation-associated silencing of TU3A in human cancers.
Awakura Y; Nakamura E; Ito N; Kamoto T; Ogawa O
Int J Oncol; 2008 Oct; 33(4):893-9. PubMed ID: 18813805
[TBL] [Abstract][Full Text] [Related]
8. HOXA5 is targeted by cell-type-specific CpG island methylation in normal cells and during the development of acute myeloid leukaemia.
Strathdee G; Sim A; Soutar R; Holyoake TL; Brown R
Carcinogenesis; 2007 Feb; 28(2):299-309. PubMed ID: 16861263
[TBL] [Abstract][Full Text] [Related]
9. GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression.
Peters I; Eggers H; Atschekzei F; Hennenlotter J; Waalkes S; Tränkenschuh W; Grosshennig A; Merseburger AS; Stenzl A; Kuczyk MA; Serth J
BJU Int; 2012 Jul; 110(2 Pt 2):E144-52. PubMed ID: 22289415
[TBL] [Abstract][Full Text] [Related]
10. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.
Urakami S; Shiina H; Enokida H; Hirata H; Kawamoto K; Kawakami T; Kikuno N; Tanaka Y; Majid S; Nakagawa M; Igawa M; Dahiya R
Clin Cancer Res; 2006 Dec; 12(23):6989-97. PubMed ID: 17145819
[TBL] [Abstract][Full Text] [Related]
11. Hypermethylation of the 5'CpG island of the FHIT gene in clear cell renal carcinomas.
Kvasha S; Gordiyuk V; Kondratov A; Ugryn D; Zgonnyk YM; Rynditch AV; Vozianov AF
Cancer Lett; 2008 Jul; 265(2):250-7. PubMed ID: 18378390
[TBL] [Abstract][Full Text] [Related]
12. Aberrant promoter methylation of DLEC1, a critical 3p22 tumor suppressor for renal cell carcinoma, is associated with more advanced tumor stage.
Zhang Q; Ying J; Li J; Fan Y; Poon FF; Ng KM; Tao Q; Jin J
J Urol; 2010 Aug; 184(2):731-7. PubMed ID: 20639048
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of BHD in sporadic renal tumors.
Khoo SK; Kahnoski K; Sugimura J; Petillo D; Chen J; Shockley K; Ludlow J; Knapp R; Giraud S; Richard S; Nordenskjöld M; Teh BT
Cancer Res; 2003 Aug; 63(15):4583-7. PubMed ID: 12907635
[TBL] [Abstract][Full Text] [Related]
14. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome.
Horiguchi A; Oya M; Shimada T; Uchida A; Marumo K; Murai M
J Urol; 2002 Aug; 168(2):762-5. PubMed ID: 12131365
[TBL] [Abstract][Full Text] [Related]
15. [Two CpG-islands of SEMA3B gene: methylation in clear cell renal cell carcinoma].
Loginov VI; Khodyrev DS; Pronina IV; Maliukova AV; Kazubskaia TP; Ermilova VD; Gar'kavtseva RF; Zabarovskiĭ ER; Braga EA
Mol Biol (Mosk); 2009; 43(6):1088-92. PubMed ID: 20088387
[TBL] [Abstract][Full Text] [Related]
16. The bcl2 -938CC genotype has poor prognosis and lower survival in renal cancer.
Hirata H; Hinoda Y; Nakajima K; Kikuno N; Suehiro Y; Tabatabai ZL; Ishii N; Dahiya R
J Urol; 2009 Aug; 182(2):721-7. PubMed ID: 19539330
[TBL] [Abstract][Full Text] [Related]
17. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors.
Costa VL; Henrique R; Ribeiro FR; Pinto M; Oliveira J; Lobo F; Teixeira MR; Jerónimo C
BMC Cancer; 2007 Jul; 7():133. PubMed ID: 17645803
[TBL] [Abstract][Full Text] [Related]
18. [Aberrant methylation of tumor suppressor genes in renal cell carcinoma].
Zhang Q; Jin J; Tao Q
Ai Zheng; 2007 Nov; 26(11):1276-80. PubMed ID: 17991333
[TBL] [Abstract][Full Text] [Related]
19. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
[TBL] [Abstract][Full Text] [Related]
20. Multigene methylation analysis of conventional renal cell carcinoma.
Onay H; Pehlivan S; Koyuncuoglu M; Kirkali Z; Ozkinay F
Urol Int; 2009; 83(1):107-12. PubMed ID: 19641369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
